Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3512-3521

  Koukourakis, Michael I ^a   Koukouraki, S ^a   Giatromanolaki, A ^a   Archimandritis, S C ^a   Skarlatos, J ^a   Beroukas, K ^a   Bizakis, J G ^a   Retalis, G ^a   Karkavitsas, N ^a   Helidonis, E S ^a  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEAD CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NECK CANCER; PRIORITY JOURNAL; SKIN TOXICITY; TISSUE DISTRIBUTION;

EID: 0032700799     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3512     Document Type: Article

References (48)

1. Cooper JS, Farnan NC, Asbell SO, et al: Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer 77:1905-1911, 1996
2. Saunders MI, Disehe S, Barret A, et al: Randomized multicenter trials of CHART vs conventional radiotherapy in head-neck and non-small cell lung cancer: An interim report. Br J Cancer 3:1455-1462, 1996
3. Marino P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta-analysis. Cancer 76:593-601, 1995
4. Koukourakis M, Hlouverakis G, Kosma L, et al: The impact of overall treatment time on the results of radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 34:315-322, 1996
5. Dillman RO, Seagien SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940-945, 1990
6. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
7. Mattson K, Holsti R, Holsti P, et al: Inoperable non-small cell lung cancer radiation with or without chemotherapy. Int J Clin Oncol 24:477-482, 1988
8. Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med. 115:681-686, 1991
9. Brodin O, Nou E, Mercke C, et al: Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinomas of the lung. Eur J Cancer 11:1892-1900, 1996
10. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
11. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
12. Bourhis J, Eschwege F: Radiotherapy-chemotherapy combinations in head-neck squamous cell carcinoma: Overview of randomized trials. Anticancer Res 16:2397-2402, 1996
13. Shewach DS, Lawrence TS: Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 23:65-71, 1996 (suppl 10)
14. Hennequin C, Giocanti N, Favaudon V: Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 56:1842-1850, 1996
15. Tamura K, Takada M, Kawase I, et al: Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88:218-223, 1997
16. Koukourakis M, Kourousis C, Kamilaki M, et al: Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer: A phase I/II dose escalation trial. Eur J Cancer 34:838-844, 1998
17. Kudoh S, Kurihara N, Okishio K, et al: A phase I-II study on weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy for unresectable locally advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 14:372, 1996 (abstr 1102)
18. Gabizon A, Catane R, Uziely B, et al: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992, 1994
19. Working PK, Newsman MS, Huang SK, Mayhew E, Vaage J, Lasic DD. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). J Liposom Res 4:667-687, 1994
20. Stewart S, Harrington KJ: The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 11:33-36, 1997 (suppl 11)
21. Bonner JA, Lawrence TS: Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol 57:55-64, 1990
22. Sherman DM, Carabell SC, Belli JA, Hellman S: The effect of dose rate and adriamycin on the tolerance of thoracic radiation in mice. Int J Radiat Oncol Biol Phys 8:45-51, 1982
23. Brooks BJ Jr, Seifter EJ, Walsh TE, et al: Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 4:200-209, 1986
24. Umsawasdi T, Valdivieso M, Booser DJ, et al: Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer 64:1995-2000, 1989
25. Valdivieso M, Burgess MA, Ewer MS, et al: Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: A prospective, randomized study. J Clin Oncol 2:207-214, 1984
26. Krakoff IH: Adriamycin (NSC-123127) studies in adult patients. Cancer Chemother Rep 6:253-257, 1975
27. Bitran JD, Goldman M: A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck: An effective salvage regimen. Am J Clin Oncol 8:61-64, 1985
28. Northfelt DW: Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma. Oncology 11:21-32, 1997 (suppl 11)
29. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
30. Ranson MR, Carmichael J, O'Byrne K, et al Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997
31. Harrington KJ, Rowlinson-Busza G, Uster PS, et al: Stealth liposome encapsulated doxorubicin (SLED) and iododeoxyuridine (SLIIUDR) as radiation sensitizers in head and neck squamous cell cancer xenograft tumors (HNSCCXT). Proc Am Soc Clin Oncol 17:230a, 1998 (abstr 881)
32. World Health Organisation: Handbook for Reporting Results of Cancer Treatment. Geneva. WHO Offset Publications, 1979, p 48
33. Koletsky A, Jahanzeb M, Radice P, et al: A randomized phase II trial of pegylated liposomal doxorubicin (PEG-LD) as second line treatment in non-small cell lung cancer (NSCLC) patients with prior exposure to platinum based therapy. Proc Am Soc Clin Oncol 17:490a, 1998 (abstr 1888)
34. Koukourakis M, Stefanaki E, Giatromanolaki A, et al: Fractionated carboplatin radiosensitization: A phase I dose escalation study. Am J Clin Oncol 21:595-601, 1998
35. Giatromanolaki A, Koukourakis M, Theodossiou D, et al: Comparative evaluation of angiogenesis assessment with anti-factor VIII and anti-CD31 immunostaining in non small cell lung cancer. Clin Cancer Res 3:2493-2500, 1997
36. Kaplan EL, Meier P, Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Lasic DD, Martin FJ, Gabizon A, et al: Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187-192, 1991
38. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am 8:431-450, 1994
39. Stewart S, Harrington KJ: The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 10:33-37, 1997 (suppl 11)
40. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95-109, 1988
41. Yuan F, Leunig M, Huang SK, et al: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in human tumor xenografts. Cancer Res 54:3352-3356, 1994
42. Dewhirst MW, Needam D: Extravasation of stealth liposomes into tumors: Direct measurement of accumulation and vascular permeability using a window chamber, in Lasic D, Martin F (eds): Stealth Liposomes. Boca Raton, FL, CRC Press, 1995, pp 127-137
43. Huang SK, Martin FJ, Jay G, et al: Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing HIV tat gene. Am J Pathol 143:10-14, 1993
44. Sakayama K, Masuno H, Miyazaki T, et al: Existence of lipoprotein lipase in human sarcomas and carcinomas. Jpn J Cancer Res 85:515-521, 1994
45. Cobbs CS, Brenman JE, Aldape KD, et al: Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 15:727-730, 1995
46. Koukourakis MI, Giatromanolaki A, Kakolyris S, et al: Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non small cell lung cancer: Impact on neoangiogenesis and survival. Br J Cancer 77:1696-1703, 1998
47. Gabizon A, Chisin R, Amselem S, et al: Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 64:1125-1132, 1991
48. Giatromanolaki A, Koukourakis MI, Georgoulias V, et al. Angiogenesis vs. response after combined chemo-radiotherapy of squamous cell head and neck cancer. Int J Cancer 80:810-817, 1999